The result suggests that patients with BCC without APC DELs and without ns-SNV in PTCH1 had the least overexpression of the genes related to inflamed T-cells and are therefore least likely to respond to ICI therapy, whereas patients with APC DELs and/or ns-SNV PTCH1 mutation have a significantly more pronounced overexpression of inflamed T-cells and may be more likely to respond to ICI therapy. This evidence concerns the gene APC and skin basal cell carcinoma.